In our previous study, we reported that elevated serum levels of miR-19a-3p, as measured at the beginning of the study (LAB08-0199), were associated with a favorable prognosis for patients with metastatic HER2 + breast cancer treated with trastuzumab [42]. Here, ERBB2 is linked to breast cancer.